Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Invo Bioscience Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
INVO
Nasdaq
3841
https://invobioscience.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Invo Bioscience Inc
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
- Jan 23rd, 2024 1:00 pm
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
- Jan 17th, 2024 1:00 pm
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal
- Dec 11th, 2023 1:00 pm
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies
- Dec 6th, 2023 2:00 pm
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
- Nov 28th, 2023 2:00 pm
INVO Reports Record Third Quarter 2023 Financial Results
- Nov 13th, 2023 9:01 pm
BestGrowthStocks.Com Issues Comprehensive Analysis Regarding INVO Biosciences Merger
- Nov 13th, 2023 1:15 pm
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger
- Nov 10th, 2023 2:00 pm
INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants
- Nov 9th, 2023 9:40 pm
Free Registration Is Now Open For Tribe Public's CEO and Q&A Presentation Webinar Event "Accelerating Biotech Value Creation" Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023
- Oct 27th, 2023 1:00 pm
INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company
- Oct 23rd, 2023 11:30 am
INVO to Participate in the Lytham Partners Fall 2023 Investor Conference
- Oct 11th, 2023 1:00 pm
INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS
- Sep 29th, 2023 8:05 pm
INVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ET
- Sep 28th, 2023 4:30 pm
INVO Reports Second Quarter 2023 Financial Results
- Aug 14th, 2023 8:05 pm
INVO Closes Acquisition of Wisconsin Fertility Institute
- Aug 11th, 2023 12:00 pm
INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
- Aug 9th, 2023 8:15 pm
INVO Bioscience Announces Closing of $4.5 Million Public Offering
- Aug 8th, 2023 5:55 pm
INVO Bioscience Announces Pricing of $4.5 Million Public Offering
- Aug 4th, 2023 1:00 pm
INVO Sets Revised Closing Date of Wisconsin Fertility Institute Acquisition and Announces Key Operational Trends to Drive Shareholder Value
- Aug 3rd, 2023 12:00 pm
Scroll